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Abstract
Background: One of today’s greatest hurdles for cancer immunotherapy is the absence of information regarding
which tumor antigens are already recognized by patients receiving immunotherapies, and whether those therapies
then boost or generate an immune response against tumor proteins. For CD8+ T cells in particular, patient-specific
immune recognition and responses at the level of individual tumor antigens are rarely characterized. Because of this,
some immunologists have turned to serum antibodies as an alternative measure of antigen-specific anti-tumor
immunity. In this work, we sought to simultaneously interrogate serum IgG and CD8+ T cell recognition of individual
tumor antigens to determine whether antigen-specific serum IgG antibodies provide a window into the behavior of
antigen-specific CD8+ T cell responses. Using antibody-based assays to evaluate immune response repertoires and
focus T cell antigen exploration could afford substantial advantages for discovering and monitoring the anti-cancer
immune responses of patients enrolled on clinical trials.
Methods: We vaccinated female BALB/c mice with a novel combination of an autophagosome-enriched vaccine
derived from 4T1 mammary carcinoma along with poly-I:C adjuvant, then screened serum for IgG binding to arrays of
15mer peptides containing known mutation sites in 4T1. Simultaneously, we primed CD8+ T cell cultures from these
same animals with 8-11mer peptides derived from these antigens. These primed T cells were then stimulated to
measure recognition of the peptides or live 4T1 cells by IFNγ release.
Results: Vaccinated animals demonstrate increases in antigen-specific CD8+ T cell recognition of 4T1 tumor cells and
peptides. For proteins confirmed in 4T1 cells and vaccine by mass spectrometry, there is a correlation between this
increased CD8+ T cell IFNγ release and serum IgG binding to individual peptide antigens.
Conclusions: These results suggest it is possible to observe some features of a patient’s antigen-specific T cell
repertoire via an antibody surrogate, which has implications for tumor antigen discovery and clinical monitoring of
antigen-specific anti-tumor immunity.
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Background
A large background of autoantibody signals to thousands
of normal human proteins is frequently observed in IgG
biomarker surveys [1–5]. On average, over 20% of the
entire surveyed human proteome is targeted by a unique
landscape of these autoantibodies in healthy individuals
[1]. Such preexisting or “natural” antibody landscapes
are thought to be the result of prior adaptive immunity
to similar peptide mimics found in commensal microbes,
foods, environmental exposures, infections, and autolo-
gous proteins. In spite of the frequency of autoantibodies
observed in humans, and the similarity between many
types of tumor antigens and autologous targets, it is not
known whether these serum antibodies or changes in
their abundance might also hint at the antigen-specific
behavior of an individual’s T cell repertoire. Others have
used antibody as a surrogate measure of antigen-specific
anti-tumor immunity [4–6], and we hypothesized that
IgG antibody signals would be more likely to overlap
with features of antigen-specific CD8+ T cell recognition
than expected by chance. Potential mechanisms for such
a relationship could occur via overlap with the under-
lying CD4+ T cell repertoire necessary for activating
both CD8+ T cells and B cells, or from antibody-aided T
cell activation via Fc receptor targeting of antigens to
antigen presenting cells. Improved understanding of the
antigen-specific relationships between antibody and T
cell responses to tumor antigens could lead to improved
immune monitoring for cancer patients and a deeper
understanding of what features define clinically-relevant
tumor antigens.
Although the overall benefit of B cell responses to
cancer remains controversial [7–9], there is a long
history of surveys for antigen-specific anti-tumor anti-
bodies [10, 11]. One type of anti-tumor immunity
increasingly recognized as important to improved out-
comes for patients with cancer are responses to
tumor-specific single nucleotide variant (SNV) neoan-
tigens [12–16], which differ by a single amino acid
from their wild-type (WT) counterpart autoantigens.
We sought to screen for IgG antibodies to peptides
centered at previously reported mutation sites in the
4T1 tumor model in both SNV neoantigen and their
WT autoantigen counterpart versions. We hypothe-
sized that patterns in these antibody profiles would
relate to the 4T1 vaccine-induced T cell recognition
of those same mutation sites. In viral immunity, there
are documented examples of IgG antibody responses
mirroring CD4+ responses at the level of individual
antigens [17–19]. Similar to the viral literature, poten-
tial links have been observed between anti-tumor
antibodies and T cell responses to specific tumor anti-
gens [20, 21], and increased antigen-specific antibody
responses have been observed in association with
improved outcomes following immunotherapy treat-
ments typically understood to depend on T cells [4, 6,
22].
Methods
Study design
For this work, we chose 4T1, a metastatic murine mam-
mary carcinoma model in BALB/c mice with a limited
number of previously described neoantigens, and a vac-
cine that is known to both work in 4T1 therapeutically
and generate cross-reactive immunity to diverse unre-
lated tumors [23, 24]. This model provided an opportun-
ity to repeatedly interrogate antigen-specific immune
responses to specific components of our vaccine in a
well-controlled system. The 4T1 tumor cell line was a
gift of Emmanuel Akporiaye (Earle A. Chiles Research
Institute, Portland, OR), from stocks received from Su-
zanne Ostrand-Rosenberg (UMBC, Baltimore, MD). Cell
line identity was confirmed identical to ATCC 4T1 and
free from Mycoplasma and other common eukaryotic
contaminants via microsatellite profiling (IDEXX
RADIL). Tumor cells were thawed directly from the
confirmed bank and passaged less than 4 times before
use. Cells were cultured in complete media consisting of
RPMI-1640 (Lonza) with 1% L-Glutamine (Lonza), 1%
Sodium Pyruvate (Lonza), 1% Non-essential Amino
Acids (Lonza), 0.1% Beta Mercaptoethanol, 50 mg/L
Gentimicine Sulfate, and 10% fetal bovine serum (Atlas
Biologicals Lot # 1070612). Production of three 4T1
autophagosome-enriched vaccine lots was performed as
previously described [23, 25]. In brief, tumor cells were
seeded into T225 flasks, grown to ~ 70% confluence, and
treated with 20 mM ammonium chloride and 100 nM
Bortezomib (Velcade) to induce autophagosome forma-
tion. Treated 4T1 cells were harvested and sonicated to
release autophagasomes. Suspended autophagasomes
were harvested with centrifugation at 12,000 G. Protein
content was measured by a BCA assay using bovine
serum albumin as a standard, and harvested 4T1
autophagosome-enriched vaccine was diluted to a pro-
tein concentration of 1 mg/mL in hetastarch vehicle and
frozen at − 80 °C until use. Age-matched 14–20 week
old female BALB/c mice (Jackson Laboratories) were
vaccinated in both inguinal nodes with a total of 10 μg
4T1 autophagosome-enriched vaccine plus 3 μg of Vac-
cigrade poly-I:C (Sigma-Aldrich) in 20 μL hetastarch
carrier, vaccine and carrier alone, poly-I:C adjuvant and
carrier alone, or left untreated. Animals were boosted
after two weeks with a single subcutaneous injection of
the same total dose in the left flank. After another two
weeks serum was harvested for analysis or mice were
challenged with 5000 live 4T1 cells in the left mammary
fat pad. Tumor growth in challenged mice was measured
thrice weekly for 30 days until immunohistochemistry
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and tumor bearing serum experiments, or until a max-
imal area of 150 mm2, which was the determinant for
death in overall survival experiments.
Multispectral IHC
Day 30 4T1 tumors were pretreated for 24 h in a zinc
solution, placed in 70% ethanol, and then paraffin em-
bedded until staining as previously described [26]. Five
μm sections were cut and fluorescently stained with
DAPI and specific antibodies to CD8a (53–6.7, BD Phar-
mingen), F4/80 (Cl:A3–1, Bio Rad), CD3 (SP7, Spring
Bioscience), FOXP3 (FJK-16 s, eBioscience), and CD4
(RM4–5, BD Biosciences) via tyramide signal amplifica-
tion. Multispectral fields were imaged with a multispec-
tral microscope (PerkinElmer, Vectra) and 15
representative 20× fields per sample were quantified
with vendor software (PerkinElmer, Inform).
4T1 whole exome sequencing and variant detection
DNA was then isolated from our 4T1 cell line bank
using a Qiagen DNeasy kit and sent to a contractor for
whole-exome sequencing (Otogenetics) at a target 50×
coverage depth. Using CLC Genomics Workbench v7.04,
the resulting Illumina FASTQ files were aligned to the
mm10 reference genome using CLC NGS core tools, a
BWS algorithm, to preserve annotations. Known SNVs
and indels in BALB/cJ versus mm10 were subtracted
using a variant file downloaded from the Sanger mouse
genome project (www.sanger.ac.uk/science/data/mouse-
genomes-project). Heterozygous non-synonymous
protein-coding variants detected > 10 times were deter-
mined to be 4T1-specific SNV mutation candidates.
4T1 15mer mutation site peptide arrays
Mutation site candidates identified from our sequencing
were compared to a list of heterozygous nonsynonymous
protein coding 4T1 SNVs identified in prior publications
[27, 28]. One of these studies reported immunologic re-
sponse data to 17 4T1 neoantigens [27], and we included
all of these previously reported immunogenic 4T1 muta-
tion sites on the arrays. As space allowed in the array de-
sign, we additionally included 66 of the 81 total
mutation sites identified by both our independent se-
quencing and confirmed by at least one of the other re-
ports. The Mouse ENSMBL protein database was
downloaded from BioMart (www.ensembl.org/biomart)
[29], and 15mer wild-type peptide sequences were ex-
tracted centered at the 75 selected coordinates. The
15mer wild-type sequences were then altered to the
identified SNV versions for a total of 150 WT and SNV
peptides. These 150 peptides were printed in triplicate
on 60 replicate custom peptide arrays along with the
known 4T1 retroviral antigen AH1 [30] and anti-mouse
IgG control spots by JPT Peptides (Berlin, Germany).
Twenty of these arrays were used in preliminary experi-
ments, and forty in follow-up experiments paired with T
cell data. Whole mouse sera were pooled from 2 to 3
animals per experimental group, diluted 1:200, and incu-
bated on the peptide arrays for one hour at 30 °C. IgG
signals were detected with a fluorescent anti-mouse IgG
secondary. All samples reacted to anti-mouse IgG con-
trol spots. Each array spot was imaged with a high reso-
lution fluorescence scanner and its intensity quantified
with GenePix spot-recognition software (Molecular De-
vices). Resulting IgG fluorescence intensity values were
averaged across each of the three replicate spots for
further analysis. In preliminary studies, the average
intensity values from all initial 20 arrays were normal-
ized simultaneously using an interquartile range trans-
formation performed using BRB-ArrayTools v4.5.0
developed by Dr. Richard Simon and the BRB-Array
Tools Development Team (brb.nci.nih.gov/BRB-Array-
Tools). These preliminary arrays are presented in Add-
itional file 1: Data file S1, and were used for selecting
antigens to additionally investigate in T cell assays. The
40 follow-up arrays paired with T cell data were analyzed
as the raw average of the three replicate spots without
such normalization, are plotted in figures, and addition-
ally included in Additional file 1: Data file S1.
In vitro T cell IFN γ release peptide assays
Antigens selected for additional profiling via IFNγ T cell
assays were selected based on a profile of the prelimin-
ary peptide array data. We selected thirty-one antigens
that spanned a range of properties: sites with a strong
preexisting IgG background signal, sites with a post-
vaccine IgG signal increase across multiple experiments,
sites with high and low predicted MHCI affinity, and mu-
tation sites without any of these distinctions but previ-
ously reported as immunogenic [27]. All experiments
were performed using pooled splenocytes from 2 to 3
individual female BALB/c mice harvested two weeks after
their second vaccination. In the case of CD8+ enriched
experiments, CD4+ cells were depleted in vivo three days
prior to spleen harvest using 200 μg of GK1.5 anti-CD4
antibody administered IP. CD4 depletion was confirmed
by flow cytometry. After ACK lysis of red blood cells, 1 ×
106 splenocytes were plated into each well of 96 well
round-bottom tissue culture plates and given primary
stimulation in complete media with 10% FBS and 5 μM of
either SNV or WT versions of mutation site peptides
manufactured by A&A Labs (San Diego, California).
15mer peptides matched the IgG arrays, and 8-11mer
minimal peptides designs were based on predicted ability
to bind MHCI. Both WT and SNV 8-11mer peptides were
based on the length and frame of the top predicted MHCI
binding minimal 8-11mer SNV peptide identified using
NetMHCpan v2.8 Server. NetMHCpan, was used to
Hulett et al. Journal for ImmunoTherapy of Cancer  (2018) 6:27 Page 3 of 14
calculate predicted H2-Kd, H2-Dd, and H2-Ld MHCI
binding scores for all possible WTand SNV 8mers, 9mers,
10mers, and 11mers that include the mutation site [31].
After 48 h of primary peptide stimulation, IL2 was added
at 10 Cetus units/mL. After an additional 96 h, contents
of each well were washed and split onto either 2° peptide
restimulation with 5 × 105 irradiated splenocytes, irradi-
ated splenocytes alone, media only, or plated onto 1 × 105
live 4T1 cells. Supernatants were harvested after an add-
itional 20 h, frozen at − 80 °C, and later analyzed for IFNγ
by ELISA.
TMT LC-MS/MS of 4T1 cells and autophagosome-enriched
vaccine
Quantitative tandem mass tag (TMT) liquid chromatog-
raphy tandem mass spectrometry (LC-MS/MS) was
performed by the Proteomics Shared Resource at Ore-
gon Health & Science University on three 4T1
autophagosome-enriched vaccine lots and three paired
samples of untreated whole 4T1 cells. Samples were
lysed using a probe sonicator and protein concentration
was estimated using BCA assay. Forty μg of protein per
sample was trypsin digested in solution. In brief, samples
were dried, dissolved in 10 μL of 4X buffer (8 M
urea,1 M Tris (pH 8.5), 8 mM CaCl2, 0.2 M methyl-
amine), reduced, alkylated, diluted to a final 2 M urea
concentration and digested by addition of 1.6 μg of
sequencing grade trypsin overnight (ProMega) Comple-
tion of the digestion was confirmed by 1-D gel analysis.
Twenty-five μg of each digested sample was then solid
phase extracted using Oasis HLB 1cm3 cartridges (Wa-
ters Corporation), and peptides dried by vacuum centri-
fugation. Samples were labeled with 10-plex TMT
reagents (Thermo Scientific), pooled together, and on-
line two dimensional reverse phase/reverse phase (RP-
RP) liquid chromatography used to separate into 9 frac-
tions at high pH, and each fraction further separated at
low pH. Peptides were analyzed using an Orbitrap Fu-
sion Mass Spectrometer (Thermo Scientific) with a syn-
chronous precursor selection MS3 TMT method [32].
Twenty μL samples (32.9 μg) were injected onto a
NanoEase 5 μM XBridge BEH130 C18 300 μM× 50 mm
column (Waters) at 3 μL/min in a mobile phase contain-
ing 10 mM ammonium formate (pH 10). Peptides were
eluted by sequential injection of 20 μL volumes of 14,
20, 22, 24, 26, 28, 30, 40, and 90% acetonitrile (ACN) in
10 mM ammonium formate (pH 10) at a 3 μL/min flow
rate. Eluted peptides were diluted with mobile phase
containing 0.1% formic acid at a 24 ul/min flow rate and
delivered to an Acclaim PepMap 100 μM× 2 cm Nano-
Viper C18, 5 μM trap (Thermo Scientific) on a switching
valve. After 10 min of loading, the trap column was
switched on-line to a PepMap RSLC C18, 2 μM, 75 μM×
25 cm EasySpray column (Thermo Scientific). Peptides
were then separated at low pH in the 2nd dimension
using a 7.5–30% ACN gradient in mobile phase contain-
ing 0.1% formic acid at 300 nL/min flow rate. Each 2nd
dimension LC run required 2 h for separation and re-
equilibration, so the entire LC/MS method required
18 h for completion. Survey scans were performed in the
Orbitrap mass analyzer (resolution = 120,000), and data-
dependent MS2 scans performed in the linear ion trap
using collision-induced dissociation (normalized colli-
sion energy = 35) following isolation with the instru-
ment’s quadrupole. Reporter ion detection was
performed in the Orbitrap mass analyzer (resolution =
60,000) using MS3 scans following synchronous precur-
sor isolation of the 10 most intense ions in the linear ion
trap, and higher-energy collisional dissociation in the
ion-routing multipole (normalized collision energy = 65).
Mass spectrometry data was processed against the
UniProt Swiss-Prot canonical mouse protein database (v.
2014_05, 16,669 sequences) with SEQUEST HT in
Proteome Discoverer v1.4 (Thermo Scientific). Search
settings were: monoisotopic parent ion mass tolerance
of 1.25 Da, monoisotopic fragment ion tolerance of
1.0 Da, tryptic cleavage with up to 2 missed cleavages,
variable modification of oxidized methionine, and static
modifications for TMT reagents (peptide N-term and ly-
sines) and alkylated cysteines. Peptide sequence assign-
ments were validated using Percolator [33] q-values (less
than 0.05) and 20 ppm delta mass agreement between
measured and theoretical peptide masses. TMT reporter
ion intensities of individual peptides were exported as
text files and processed with in-house scripts. A median
reporter ion intensity cutoff of 1500 was used to reject
low quality peptides, and all reporter ion intensities for
unique peptides matched to each respective protein were
summed to create total protein intensities. A minimum
of 2 peptides contributing to the protein total was re-
quired for each identification to improve data quality.
Protein identification, quantitative information, and add-
itional UniProt annotations were tabulated for all pro-
teins and are listed in Additional file 1: Data file S1. A
total of 4416 proteins were identified and quantification
was done on 4196 proteins (excluding contaminants).
Only this discovery confirmation, and not quantitative
abundance, was used to separate experimental groups in
Fig. 6, and Additional file 2: Figures S5–7.
Statistical analyses
Analyses were performed on either summary data or in-
dividualized experiments, and this information is placed
alongside the specific type of test performed and p-value
(P) within the figure legends. All statistical tests were
considered significant at the P < 0.05 level and were per-
formed with Prism 7 (GraphPad). In general, parametric
comparisons were either two sample t-tests or paired t-
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tests, and non-parametric tests were Wilcoxon matched-
pairs signed rank tests. Significance of all correlations was
determined by linear regression and Pearson correlation
coefficient. Graphs and statistics in Figs. 2, 3, 4, 5, and 6
and Additional file 2: Figures S3–7 can be recreated from
values presented in Additional file 1: Data file S1.
Results
We have previously demonstrated the benefits of our
tumor cell-derived autophagosome-enriched vaccine
model [23–25, 34], a vaccine that has demonstrated both
prophylactic and therapeutic efficacy against both syn-
geneic and unrelated tumors. This vaccine platform is
currently in clinical trials, and has demonstrated in-
creased therapeutic efficacy when combined with anti-
OX40 for the treatment of established 4T1 [24], a meta-
static mammary carcinoma model with established se-
quencing and neoantigen immunity data [27, 28, 35]. In
order to evaluate the immune response induced by this
vaccine, independent of the effect of a progressively
growing tumor, naïve tumor-free BALB/c mice were
studied. Animals received a 4T1 autophagosome-
enriched vaccine + poly-I:C adjuvant injected into the
inguinal lymph nodes of naïve female BALB/c mice. A
single booster vaccination was given subcutaneously at
2 weeks, and, at 4 weeks, animals were killed for sera
harvests or challenged with live 4T1 tumor cells (Fig. 1a).
Challenged animals that had received prophylactic 4T1
autophagosome-enriched vaccine + poly-I:C, but not ei-
ther alone, benefitted from a significant delay in tumor
growth (Fig. 1b), results similar to our prior publications.
Additionally, the only group that demonstrated a statisti-
cally significant increase in long-term survival was the
combination treatment (Fig. 1c). It should be noted that
while the level of protection is small, 4T1 is considered
to be a poorly immunogenic tumor as vaccination with
irradiated 4T1 tumor cells fails to protect any animals
from a tumor challenge [36]. Additionally, when this
4T1 autophagosome vaccine is combined with a T cell
agonist, anti-OX40, therapeutic efficacy is signifi-
cantly increased [24]. We next sought to determine
whether there were any differences in intratumoral T cell
infiltrates in these tumors by immunohistochemistry
that would help explain the treatment benefit; numerous
studies have linked increased T cell infiltrate with im-
proved outcomes following original work by Galon
and colleagues [37]. We stained sections from day 30
4T1 tumors as previously reported [26] for CD3, CD4,
CD8, FOXP3, and F4/80 and quantified the infiltrates.
Versus all other groups, including adjuvant-only con-
trols, combination vaccinated animals demonstrated an
increase in CD3 + CD8+ infiltrates (Fig. 1d, e). Versus
adjuvant-only controls, these same tumors demonstrated
no difference in CD3 + CD4 + FOXP3- or CD3 + CD4 +
FOXP3+ infiltrates (Additional file 2: Figure S1A, B). These
results demonstrate that our combination autophagosome-
enriched vaccine creates increased frequencies of CD8+ T
cells that are capable of trafficking to 4T1 tumors in vivo.
These results correlate with delayed in vivo tumor growth
similar to previous clinical reports [37].
We next sought to determine whether IgG antibodies
could be used to indicate immunity to known mutation
sites in 4T1 after treatment with our vaccine model. We
were led to this by others whose observations have sug-
gested links between IgG antibody and T cell responses
to human tumor antigens [6, 21]. We isolated DNA and
performed whole-exome sequencing on our 4T1 cell
bank, and used the sequencing data to identify heterozy-
gous single nucleotide variants by comparison to a fe-
male BALB/cJ reference sequence; subsequently referred
to as SNVs. We used SNVs that were both identified in
previous reports [27, 28, 35] and confirmed by our se-
quencing to design a custom 15mer peptide array for 75
SNV neoantigens and 75 alternate allele wild type (WT)
autoantigens centered at 4T1 mutation sites, as well as
the known retroviral antigen AH1 [30] (Additional file 2:
Figure S2). A number of these mutation sites have been
previously reported as immunogenic to murine CD4+ or
CD8+ T cells [27]. Each array contained all peptides
printed in triplicate along with anti-mouse IgG controls.
We ran preliminary IgG arrays with sera harvested from
animals used in the tumor challenge and in vitro experi-
ments already presented (Fig. 1a-e), and these prelimin-
ary arrays were used to identify outlier antigens of
interest for final IgG array experiments paired with IFNγ
T cell assays. Data from both preliminary IgG arrays and
final IgG arrays paired with T cell IFNγ release data are
available (Additional file 1: Data file S1).
The serum array data demonstrate IgG binding signals
against 4T1 peptides from both naïve and vaccinated
animal sera, with increased average IgG signals in vac-
cine groups against many individual WT autoantigen
15mer peptides (Fig. 2a), and SNV neoantigen 15mer
peptides (Fig. 2b). The IgG signals to both WT and SNV
4T1 peptides were significantly higher in sera from vac-
cinated animals (Fig. 2c), but these increased IgG signals
after vaccination did not significantly favor SNV neoan-
tigen over WT autoantigen peptides (Fig. 2d). However,
there were stronger overall IgG signals against SNV pep-
tides in serum from both naïve (Fig. 2e) and vaccinated
(Fig. 2f ) animals, suggesting a background landscape of
preexisting serum antibodies that favors neoantigens
over autoantigens.
Prior to the final IgG array experiments presented in
Fig. 2, we had used preliminary IgG arrays to identify a
number of 4T1 antigens which had strong increases in
IgG signals after vaccination or strong preexisting IgG
signals in naïve animals. We used these results to select
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a smaller set of antigens for investigation in parallel T
cell assays, and ran these T cell assays with splenocytes
from the same animals whose serum IgG was analyzed
in Fig. 2. These T cells were stimulated with either
15mer peptides matching the IgG array or predicted
MHCI binding 8-11mer peptide designed with MHCI
prediction software [31]. The chosen mutation sites are
listed in relation to IgG array data in Additional file 1:
Data file S1, and were tested as both WT autoantigen
and SNV neoantigen peptides.
T cells from vaccinated animals have increased recog-
nition of both WT and SNV 8-11mer 4T1 peptides
(Fig. 3a-b), and serum from these vaccinated animals
also demonstrates increased IgG binding to 15mer
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Fig. 1 Prophylactic autophagosome vaccination delayed 4T1 tumor growth, improved overall survival, and increased intratumoral CD3 + CD8+
infiltration. a Mice were vaccinated in both inguinal lymph nodes with 4T1 autophagosome-enriched vaccine plus poly-I:C, vaccine alone,
adjuvant alone, or left untreated. Animals were boosted subcutaneously after two weeks. After another two weeks, sera or spleens were harvested
at Day 0 for in vitro antibody and T cell assays or animals were challenged with live 4T1 tumor cells for survival endpoints, tumor bearing sera,
and immunohistochemistry. b Upon challenge, reduced average tumor growth was observed in combination vaccine + poly-I:C pretreated
animals with maximum separation occurring at Day 22 versus poly-I:C alone (P = 0.04) and Day 27 versus naïve animals (P = 0.002) by Dunnett’s
multiple comparisons test. Data were pooled from five independent experiments with error bars plotted as the standard error of the mean. c
Overall survival was improved in combination treatment versus all other groups (P = 0.02) by Gehan-Breslow-Wilcoxon test. Data were pooled
from three independent experiments. d-e Zinc and alcohol fixed day 30 4T1 tumors were stained for six color immunohistochemistry with
tyramide signal amplification. d Three color representative image showing CD8+ (red), F4/80 (green), and DAPI (blue). e Fifteen 20× fields were
imaged for each of 4 to 6 tumors per group and quantified for CD3 + CD8+ per mm2 (fields from individual tumors colored separately). Higher
numbers of CD3 + CD8+ infiltrates were seen in the fields from vaccine + poly-I:C pretreated tumors versus all other groups (P < 0.0001) by t-test.
Lines plotted are the median and interquartile range
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peptides containing this same group of mutation sites
(Fig. 3c-d). For several of these 4T1 antigens, we ob-
served simultaneous increases in IgG 15mer signal in-
tensity and T cell recognition of 8-11mer peptides for
specific antigens in vaccinated animals (Fig. 3e). A simi-
lar result was observed for splenocyte assays involving
WT 15mer peptides (Additional file 2: Figure S3A-E),
but naïve splenocytes were additionally able to recognize
SNV 15mer peptides after our culture process. Because
of this increased naïve recognition we did no further ex-
periments with 15mer peptides.
Since we observed increased recognition of 8-11mer
4T1 peptides by T cells from vaccinated animals, and
initial immunohistochemistry experiments suggesting a
greater role for CD3 + CD8+ cells than CD3 + CD4+
cells for tumor control in this model (Fig. 1 d,e; Add-
itional file 2: Figure S1A,B), we next sought to confirm
the role of CD8+ T cells with an enriched population of
a
b
c d
e f
Fig. 2 Vaccinated animal sera had increased IgG antibodies to peptides centered at mutation sites in 4T1. a-f Data are from five independent
pairs of IgG arrays reacted with pooled naïve or vaccinated mouse serum. Each array consists of 151 15mer peptides printed in triplicate and
centered at WT autoantigen and SNV neoantigen mutation-sites in 4T1. a Average serum IgG fluorescence signal intensity versus 15mer peptides
centered at WT versions of listed 4T1 mutation-sites in naïve and vaccinated animals sorted by the combined WT and SNV IgG signals observed
in naïve animals. b Average serum IgG fluorescence signal intensity versus 15mer peptides centered at SNV versions of listed 4T1 mutation-sites
in naïve and vaccinated animals sorted by the combined WT and SNV IgG signal observed in naïve animals. c-d Data are plotted as average
values, but statistics are computed from all individualized pairs of experimental values. c Vaccinated animals demonstrated increased serum IgG
signal intensity to a WT and SNV 15mer peptides (P < 0.0001) by Wilcoxon matched-pairs signed rank test, (d) but these observed increases in IgG
signal intensity from vaccine groups were not significantly higher for SNV peptides than WT peptides (P = 0.26) by Wilcoxon matched-pairs signed
rank test. However, there are stronger IgG signal intensities for SNV neoantigens than paired WT autoantigens in serum from both (e) naïve
animals (P < 0.0001), and (f) vaccinated animals (P < 0.0001) by Wilcoxon matched-pairs signed rank test
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CD8+ T cells. Experiments were performed as before
except with the addition of a CD4-depleting antibody in
vivo prior to spleen harvest. Compared to naïve animals,
vaccinated animals demonstrated stronger CD8+ T cell
IFNγ recognition of both WT autoantigen and SNV
neoantigen 8-11mer peptides from 4T1 (Fig. 4a,b). Inter-
estingly, Serum from these vaccinated animals also dem-
onstrated a significantly (p < 0.0001) increased IgG
binding to 15mer WT peptides as well as 15mer SNV
peptides containing these mutation sites (Fig. 4c,d), and
there was a significant (p = 0.0039) correlation between
increased IgG binding to 15mer peptides after vaccin-
ation and increased IFNγ recognition of both the WT
and SNV 8-11mer peptides by CD8+ T cells. This sug-
gests that at least in some cases, vaccination with an
autophagosome vaccine leads to the development of a
a
e
b c d
Fig. 3 Simultaneous increases in IgG signals to 15mers and splenocyte IFNγ recognition of individual 8-11mer antigens. Serum and splenocytes
were harvested from naïve and 4T1 autophagosome-enriched vaccine + poly-I:C vaccinated animals. Serum was run on the 15mer arrays
presented previously (Fig. 2). Splenocytes were stimulated with WT and SNV versions of top predicted MHCI binding 8-11mer mutation site
peptides for 48 h, then expanded on IL2 for an additional 96 h before wells were split and restimulated with either naïve splenocytes or naïve
splenocytes pulsed with a second stimulation of peptide. Graphs are of the average increase in IFNγ secretion by ELISA in wells with peptide
restimulation over splenocytes alone for n = 3 experiments with vaccine groups and n = 2 experiments with naïve groups. a, b Increase in average
IFNγ secretion in vaccine groups upon secondary exposure to n = 15 different WT (P = 0.002) (a) and n = 15 different SNV (P = 0.005) peptides (b)
by Wilcoxon matched-pairs signed rank test. c, d Simultaneous serum IgG array recognition data for 15mer peptides centered at these same
mutation sites from the same n = 3 vaccine groups and n = 2 naïve groups used in splenocyte assays. Increase in average IgG signal intensity to
n = 15 different WT (P = 0.01) (c) and n = 15 different SNV (P = 0.02) (d) peptides by Wilcoxon matched-pairs signed rank test. e Combined data
previously presented in (a-d) plots average differences in IgG and IFNγ recognition for each of the n = 15 WT and n = 15 SNV mutation sites along
with AH1. Positive values represent increased signals in vaccine groups and negative values represent increased signals in naïve groups. Values in
upper-right quadrant demonstrated simultaneous increases in IgG and splenocyte IFNγ recognition of individual 4T1 mutation-site antigens in
vaccine groups. However, there was no significant overall correlation of these increases in recognition (P = 0.6) by Pearson correlation coefficient
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coordinated immune response that results in CD8+ T
cell antigen recognition in tandem with increased IgG
antibody recognition of those same tumor peptides.
In order to determine the relevance of these results to
tumor recognition, we performed two of the CD4-
depleted experiments with additional restimulation
groups of live 4T1 tumor cells. In vitro priming of CD8+
T cells from vaccinated animals with 8-11mer WT
autoantigen peptides produced tumor recognition in
three cases, but not as an overall group (Fig. 5a). In con-
trast, a larger fraction of CD8+ T cells from vaccinated
animals stimulated with 8-11mer SNV neoantigen pep-
tides demonstrated improved 4T1 tumor recognition
(Fig. 5b). It is interesting to note that when evaluating
the development of strong IFN-γ responses, arbitrarily
set at 1000 pg, WT peptides induced 3 strong responses
a
e
b c d
Fig. 4 Simultaneous increases in IgG signals to 15mers and CD8+ IFNγ recognition of individual 8-11mer antigens. Serum and CD4-depleted
splenocytes were harvested from naïve and 4T1 autophagosome-enriched vaccine + poly-I:C vaccinated animals. Serum was run on the 15mer
arrays presented previously (Fig. 2). CD4-depleted splenocytes were stimulated with WT and SNV versions of top predicted MHCI binding 8-11mer
mutation site peptides for 48 h, then expanded on IL2 for an additional 96 h before wells were split and restimulated with naïve splenocytes
pulsed with a second stimulation of peptide. Graphs are of the IFNγ secretion for each individual paired experiment from n = 3 paired replicates
with vaccine and naïve groups, each involving n = 15 different WT and n = 15 SNV peptide experiments. a, b Increase in IFNγ secretion in vaccine
groups upon secondary exposure to n = 45 paired experiments with WT peptides (P < 0.0001) (a) and n = 45 paired experiments with SNV (P =
0.005) peptides (b) by Wilcoxon matched-pairs signed rank test. c, d Simultaneous serum IgG array recognition data for 15mer peptides centered
at these same mutation sites from the same n = 3 vaccinated animal groups and n = 3 naïve groups used in splenocyte assays. Increase in average
IgG signal intensity to n = 45 paired WT peptide experiments (P < 0.0001) (c) and n = 45 SNV peptide experiments (P < 0.0001) (d) by Wilcoxon
matched-pairs signed rank test. e Combined data previously presented in (a-d) plots average differences in IgG and IFNγ recognition for each of
the n = 45 WT experiments and n = 45 SNV experiments. Positive values represent increased signals in vaccine groups and negative values
represent increased signals in naïve groups. Values in upper-right quadrant demonstrated simultaneous increases in IgG and splenocyte IFNγ
recognition of individual 4T1 mutation-site antigens in vaccine groups. There was a significant overall correlation of these increases in IgG and
CD8+ IFNγ recognition (P = 0.0039) by Pearson correlation coefficient
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and the SNV peptides induced 4 strong responses. Simi-
lar to previous results, this coincided with increased IgG
antibody to both WT and SNV 15mer versions of these
mutation sites (Fig. 5c,d), which often resulted in simul-
taneous improvements in IgG and tumor recognition re-
lated to specific 4T1 SNV neoantigens (Fig. 5e). Though
not directly correlative for the whole group of candidate
4T1 antigens, there were several post-vaccine IgG signal
increases which matched the antigens that improved
CD8+ T cell responses against 4T1 tumor.
Our IgG array data demonstrated that many of the
strongest vaccine-induced antibody responses to 4T1
peptides could be detected, albeit at lower levels, in
naive animals (Additional File 2: Fig. S4).
In order to confirm that we had observed stronger im-
mune responses to proteins from our 4T1 vaccine, we
a
e
b c d
Fig. 5 Simultaneous increases in IgG signals to 15mers and improvements in CD8+ IFNγ recognition of tumor. Serum and CD4-depleted splenocytes
were harvested from 4T1 autophagosome-enriched vaccine + poly-I:C vaccinated animals. Serum was run on the 15mer arrays presented previously
(Fig. 2). CD4-depleted splenocytes were stimulated as presented previously (Fig. 4), then placed in empty wells or restimulated with 4T1 tumor cells.
Graphs are of the IFNγ secretion for each individual paired experiment from n = 2 paired replicates with CD8+ T cells only or CD8+ T cells plus live
4T1 cells, each pair initially stimulated with one of n = 15 WT or n = 15 SNV peptides. a, b IFNγ secretion in 4T1 tumor restimulated groups demon-
strated outliers, but no overall increased 4T1 recognition after primary exposure to n = 30 paired experiments with WT peptides (P = 0.65) (a), but did
show overall increased 4T1 recognition after primary exposure to n = 30 paired experiments with SNV peptides (P = 0.0002) (b) by Wilcoxon matched-
pairs signed rank test. c, d Simultaneous serum IgG array recognition data for 15mer peptides centered at these same mutation sites from the same n
= 2 vaccinated animal groups used in splenocyte assays and n = 2 naïve group controls. Increase in average IgG signal intensity to n = 30 paired WT
peptide experiments (P < 0.0022) (c) and n = 30 SNV peptide experiments (P < 0.0001) (d) by Wilcoxon matched-pairs signed rank test. e Combined
data previously presented in (a-d) plots average differences in IgG and IFNγ recognition for each of the n = 30 WT experiments and n = 30 SNV
experiments. Positive values represent increased IgG signals versus naïve controls and increased IFNγ recognition of 4T1 tumor over T cells only. Values
in upper-right quadrant demonstrated increases in serum IgG recognition of that antigen, and a simultaneous ability for that antigen to improve CD8+
T cell IFNγ recognition of live 4T1 cells. However, there was no significant direct correlation of these increases in IgG and CD8+ IFNγ recognition (P =
0.95) by Pearson correlation coefficient
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performed quantitative tandem mass tag (TMT) liquid
chromatography tandem mass spectrometry (LC-MS/
MS) on both our 4T1 cell bank and the 4T1
autophagosome-enriched vaccine lots used in these stud-
ies to a depth of 4416 proteins. A number of the anti-
gens studied in the T cell and IgG assays were confirmed
as being found by TMT LC-MS/MS at a depth of 4416
confirmed tumor proteins. The results of this TMT LC-
MS/MS data are available (Additional file 1: Data file
S1). Although the observed increases in IgG recognition
after vaccination did not depend on mass spectrometry
identification for the 30 antigens investigated in T cell
assays (Fig. 6a), or for other peptides on the IgG arrays
(Additional file 2: Figure S5), there was an overall in-
crease in CD8+ T cell recognition of WT and SNV 8-
11mer peptides from proteins confirmed in the vaccine
by TMT LC-MS/MS (Fig. 6b). These results translated
to the IgG and CD8+ T cell correlation data presented
previously (Fig. 4e), where we observed that the correl-
ation between increased IgG signals and IFNγ release
after vaccination occurred in the mass spectrometry
positive fraction of the assays (Fig. 6c,d). Finally, we
filtered the 4T1 tumor recognition data presented (Fig.
5a-d) for mass spectrometry identification, and observed
a relationship between serum IgG signals against an
antigen, and that antigen’s ability to improve recognition
of 4T1 tumor. A more extensive breakdown of the indi-
vidual results for mass spectrometry confirmed peptide
recognition (Additional file 2: Figure S6) and tumor rec-
ognition (Additional file 2: Figure S7) is presented.
These results suggest that the increased CD8+ T cell
recognition observed is an antigen-specific response in-
duced by our vaccine, which in turn correlates to an IgG
antibody profile that strengthens, but also exists prior to
treatment.
Discussion
We observed IgG antibodies to 4T1 peptides in naïve fe-
male BALB/c mice, and this population of antibodies
demonstrates stronger recognition of neoantigen pep-
tides than autoantigen counterpart peptides which differ
by a single amino acid. This result suggests a bias for
Fig. 6 Simultaneous vaccine-induced IgG and CD8+ IFNγ recognition of 4T1 tumor and peptides confirmed by LC-MS/MS. LC-MS/MS was
performed to determine whether proteins containing the 4T1 peptides were present in live 4T1 cells and 4T1 autophagosome-enriched
vaccine. Of the 15 4T1 WT and SNV pairs additionally analyzed in T cell assays, there were n = 9 WT and SNV antigen pairs from proteins
confirmed in 4T1 by mass spectrometry and n = 6 WT and SNV antigen pairs not confirmed by mass spectrometry. a-d Data shown are from
experiments previously presented in Fig. 4. Vaccinated animals demonstrated increased serum IgG to the peptides analyzed in T cell assays;
however, there was no improved IgG response (a) to the WT and SNV peptides confirmed by mass spectrometry over unconfirmed proteins
(P = 0.1) by unpaired t-test. However, confirmed presence of the antigenic protein in the vaccine by mass spectrometry (b) resulted in improved
IFNγ secretion in vaccine groups upon secondary exposure to WT and SNV 4T1 8-11mer peptides (P = 0.04) by unpaired t-test. There was no
significant overall correlation of these increases in IgG and CD8+ IFNγ peptide recognition (c) for peptides unconfirmed by mass spectrometry
(P = 0.75), but there was a significant correlation between improvements in IgG and CD8+ IFNγ peptide recognition (d) for mass spectrometry
confirmed proteins (P = 0.01) by Pearson correlation coefficient. For 4T1 tumor recognition data previously presented in Fig. 5, WT and SNV
antigens from proteins confirmed in 4T1 cells and vaccine by mass spectrometry (e) produced greater CD8+ IFNγ recognition of 4T1 cells if serum
from those animals also had higher IgG recognition of those antigens
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the recognition of certain antigens prior to tumor expos-
ure, perhaps caused by an individual’s unique history of
tolerance to autoantigens or prior exposure to cross-
reactive foreign antigens. Recent work has demonstrated
a dramatic dependence of checkpoint blockade immuno-
therapies on specific microflora [38, 39], an effect typic-
ally ascribed to global cytokine changes, but perhaps
also due in part to bacterial antigen cross-reactivity with
tumor antigens. Germ free animals lacking such im-
munologic history do not respond well to cancer therapy
[40]. The correlations between vaccine-induced T cell re-
sponses and antigen-specific IgG antibody signals ob-
served in this study suggest that IgG may be one
biomarker to observe such relationships between past
immunologic history and future or ongoing anti-tumor
immunity. And beyond the potential role of antibody as
a biomarker, antibody may be directly involved in trans-
ferring prior immunologic knowledge to help prime or
boost T cell populations.
Antigen-specific antibody can increase T cell activation
through improved antigen uptake and cross presentation
by antigen presenting cells in mice [41], and a similar Fc
receptor dependent effect has also been observed in
humans: some patients receiving monoclonal antibodies
to EGFR (Cetuximab) generate elevated circulating
EGFR853–861–specific CD8+ T cells [42]. Therefore, anti-
bodies that happen to bind a tumor peptide or protein –
such as those observed in this work – could provide a
mechanism for improved CD8+ responses to those same
antigens via increased cross-presentation efficiency. In
addition to the overall trends we observed between IgG
and CD8+ responses, we were struck that minimal pep-
tides from Wdr33:H13Y – a mutation site with strong
preexisting IgG signals in naïve animals – were recog-
nized regularly in vaccinated animals by IgG and pro-
duced large increases in CD8+ T cell recognition of both
4T1 tumor and Wdr33:H13Y peptides. This exemplary
case builds on our overall hypothesis that some antigen-
specific CD8+ T cell responses to our vaccine are add-
itionally favored by B cell and/or CD4+ recognition of
similar peptides. While the mechanism is still uncertain,
the observations reported here warrant further investiga-
tion into the roles of IgG and other antibody isotypes on
future anti-tumor responses. Future work should focus
on isotype-specific relationships and include data from
clinical samples; this will be essential to determine these
nuances of antibody and T cell interrelationships.
In the viral literature, the dependence of future
responses on past ones to similar antigens is well docu-
mented [43–46], and there are recent reports suggesting
that preexisting immunity not only occurs, but is com-
mon; many healthy adults have memory T cells reactive
to peptides from viruses they have never encountered
[47]. Perhaps such T cell repertoires relate to the
observed universe of preexisting IgG autoantibodies
common in humans [1]. If true, these IgG antibodies
may help point to the types of antigens targeted by – or
that evade – cancer immune surveillance. We may find
that some patients require not just a release of tolerance
or boosting of the natural priming environment by
checkpoint blockade, but perhaps vaccines and therapies
directed toward those antigens inadvertently avoided by
their own unique history of antigen exposure. In the
future, it may be possible to determine this antigenic
history and correct gaps in immune surveillance with
either personalized cancer vaccines or generalized com-
plex vaccines like the autophagosome-enriched vaccine
studied here.
Conclusion
This study presents a simultaneous characterization of
humoral and cellular immunity to tumor antigens at the
level of individual peptides from a vaccine model whose
components are currently undergoing human clinical
trials [48, 49], and provides rationale for further investi-
gation into the role of preexisting and post-treatment
anti-tumor antibodies on anti-tumor CD8+ T cell im-
munity. Though this work focuses on neoantigens and
autoantigens centered at mutation sites, these results
may translate to other antigen populations, including
non-mutated tumor antigens with ectopic expression
patterns and antigens related to non-cancer diseases.
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